Insights

Responding to Examiner Rejections in Chem/Pharma/Bio Applications

by Chad M. Rink and Briana Barron | Patent Law Institute

BSKB’s Chad Rink recently co-lectured with Briana Barron during the 2022 Patent Law Institute (PLI) virtual meeting. Their topic was “Responding to Examiner Rejections in Chem/Pharma/Bio Applications.” Chad and Briana discussed recent court decisions covering written description, obviousness, and inequitable conduct.

Label Ruling Upends Generic Medicine Makers

by MaryAnne Armstrong | WIPR

The effects of the ‘skinny label’ decision are being felt across pharma. MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch revisits GSK v Teva.

Podcast: Leonard Svensson (BSKB) remarks on Impossible Food’s recent legal issues

by Podcast Host, June Grasso | Bloomberg Law Podcast

In this week's Bloomberg Law Podcast, BSKB’s Leonard Svensson is featured discussing how “Impossible Foods is testing a tastes-like-meat patent in court.”

Patent applications: Kite raises the game

by Hailey Bureau and Olayinka Oladele | Patent applications: Kite raises the game

Hailey Bureau, Ph.D. (Associate) and Olayinka Oladele (Law Clerk from Texas Southern University's Thurgood Marshall School of Law) recently co-authored and article for WIPR regarding the Federal Circuit's recent "added complexities to the drafting of patent applications for antibody inventions" as a result of the cases Amgen v Sanofi (2021) and Juno Therapeutics v Kite Pharma (2021).

Eugene Perez weighs in on the “Restoring America Invents Act”

by Eileen McDermott | IPWatchdog

Eugene Perez weighs in on the “Restoring America Invents Act”, proposed by Senators Leahy (D-VT) and Cornyn (R-TX), in an article from IPWatchdog, Inc

Q&A with David Bilodeau and Brad Fritz: Rain Computing v. Samsung

by David Bilodeau, Brad Fritz, and Tom Phillips | WIPR Patents Live

WIPR Patents Live hosted BSKB Attorneys David Bilodeau (Partner) and Brad Fritz (Associate) in a Q&A with Tom Phillips regarding Rain Computing v. Samsung.

MaryAnne Armstrong, PhD, offers her perspective on the "impact of the America Invents Act"

by Eileen McDermott | IPWatchdog

MaryAnne Armstrong, PhD, offers her perspective on the "impact of the America Invents Act" during the bill's 10 year anniversary in an article from IPWatchdog, Inc.

When the Inventor is Artificial

by MaryAnne Armstrong, Ph. D. | LSIPR

MaryAnne Armstrong discusses whether the same tests for non-obviousness of biotech patents will be applied to pharma inventions developed using AI.

Industry Reacts to the Supreme Court’s Arthrex Ruling: Chaos Averted – or Just Delayed?

by | IPWatchdog

Partner, Eugene T. Perez was recently quoted in an article by IPWatchdog regarding this week's U.S. Supreme Court patent decision in United States v. Arthrex, Inc. Et Al.

Q&A with MaryAnne Armstrong: The future of AI in the life sciences

by MaryAnne Armstrong, Ph. D. | LSIPR

MaryAnne Armstrong, Ph. D., sits down with LSIPR to discuss artificial intelligence's impact on IP industry relating to life sciences and pharmaceuticals.

Substitute/Cultivated Meat Technology: A Deep-Dive Patent Landscape Analysis

by Leonard R. Svensson, Esq. | Birch, Stewart, Kolasch & Birch, LLP

Substitute/Cultivated Meat Technology: A Deep-Dive Patent Landscape Analysis by Leonard R. Svensson, Esq.

Energetics and structure of alanine-rich α-helices via adaptive steered molecular dynamics

by Co-author Hailey R. Bureau, Ph.D. | Biophysical Journal

David A. Bilodeau named to Best Lawyers® list

by | BSKB News

Birch, Stewart, Kolasch & Birch, LLP is pleased to announce that David A. Bilodeau has been included in this Edition of The Best Lawyers in America.

Printed publications: an evolving doctrine

by Eugene T. Perez | Printed publications: an evolving doctrine

While the PTAB’s decision in Hulu provides some guidance for post-grant proceedings, there is still no bright-line rule as to what constitutes a “printed publication”. Eugene Perez of Birch Stewart Kolasch Birch examines current case rulings.

BSKB ASSISTS CLIENT IN SUCCESSFUL IPR CHALLENGES TO BIOPHARMACEUTICAL PATENTS FOR TREATING POMPE DISEASE

by Gerald M. Murphy, Jr. | BSKB News

BSKB assists client in successful IPR Challenges to Biopharmaceutical Patents for Treating Pompe Disease

Washington, D.C. NFL Team Loses Race to the Trademark Office: Does it Matter?

by Michael. T Smith | IPWatchDog

In surveys throughout the Washington, D.C. metro area, three possible replacement names have emerged as favorites among the fans: Warriors, Red Wolves, and Redtails. Armed with the knowledge of the name change and the relative popularity of the possible replacement names, two enterprising individuals have applied to obtain a federal trademark registration for the marks WARRIORS, WASHINGTON RED WOLVES, and WASHINGTON REDTAILS, respectively. Neither applicant appears to be connected to the owners of the Washington D.C. professional football team.

Could good intentions lead to future danger?

by MaryAnne Armstrong, Ph.D. | LSIPR

MaryAnne Armstrong, Ph.D. discusses the potential risks to IP rights with open-access to technology, medicines and devices in the fight against COVID-19 in the latest issue of LSIPR.

Indefinite claims at the PTAB

by Chad M. Rink and Hailey R. Bureau, Ph.D. | World Intellectual Property Review

Chad Rink and Hailey Bureau, Ph.D. talk about indefinite claims at the PTAB and alternative routes in WIPR- Issue 1.

The relative stability of trpzip1 and its mutants determined by computation and experiment

by Hailey R. Bureau, Stephen Quirk and Rigoberto Hernandez | RSC Advances

Six mutants of the tryptophan zipper peptide trpzip1 have been computationally and experimentally characterized. We determine the varying roles in secondary structure stability of specific residues through a mutation assay. Four of the mutations directly effect the Trp–Trp interactions and two of the mutations target the salt bridge between Glu5 and Lys8. CD spectra and thermal unfolding are used to determine the secondary structure and stability of the mutants compared to the wildtype peptide. Adaptive steered molecular dynamics has been used to obtain the energetics of the unfolding pathways of the mutations. The hydrogen bonding patterns and side-chain interactions over the course of unfolding have also been calculated and compared to wildtype trpzip1. The key finding from this work is the importance of a stabilizing non-native salt bridge pair present in the K8L mutation.

Antibody patents: Danger ahead for biologics

by John H. Heithaus and Gerald M. Murphy | Life Science IP Review

John Heithaus and Gerald Murphy discuss the evolution of antibody written description standards at the USPTO.  Read more of their article featured in Life Science IP Review.